Skip to content

Phase III Study of HP-3150 in Patients with Low Back Pain

Phase III Study of HP-3150 in Patients with Low Back Pain

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080225040
Enrollment
686
Registered
2020-01-28
Start date
2020-02-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low back pain

Interventions

Sponsors

Hisamitsu Pharmaceutical Co., Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - A patient who was clinically diagnosed with low back pain not less than 12 weeks ago. - A patient who has been treated with NSAIDs or acetaminophen for low back pain for not less than 4 weeks and has not changed their dosage and dose regimen within 4 weeks.

Exclusion criteria

Exclusion criteria: - A patient in whom pain in the low back of assessment cannot be assessed appropriately because she/he suffers pain due to complications. - A patient with serious blood abnormality, liver disorder, renal disorder, hypertension, cardiac dysfunction, or other clinically problematic complications. - A patient with malignancy. - A patient with peptic ulcer. - A patient with current or past history of aspirin-induced asthma. - A patient with past history of hypersensitivity to NSAIDs. - A patient who is pregnant, parturient, suspected of being pregnant, or breast-feeding. - A patient who is known to have dermal sensitivity to external preparations or tapes such as adhesive tapes. - A patient in whom a planned site of application cannot be secured due to skin abnormality, tattoos or birthmarks, or a patient who frequently gets tanned.

Design outcomes

Primary

MeasureTime frame
efficacy confirmatory - Change from baseline in the visual analog scale values

Secondary

MeasureTime frame
safety efficacy - Change from baseline in scores of the Roland-Morris Disability Questionnaire - Adverse events, laboratory test values, vital signs, ECG

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026